The relationship between non-alcoholic fatty liver disease and small intestinal bacterial overgrowth among overweight and obese children and adolescents (original) (raw)

Abstract

Background:

The increasing rate of obesity and overweight among children has highlighted nonalcoholic fatty liver disease (NAFLD) as the most common cause of chronic pediatric liver diseases. There are many publications supporting the idea that gut microbiota is altered in NAFLD. The aim of this study was to evaluate the prevalence of NAFLD among overweight and obese children with and without small intestinal bacterial overgrowth (SIBO) compared to a control group and to assess if intestinal dysbiosis represents a risk factor for NAFLD.

Methods:

One hundred and twenty-five overweight and obese children aged 10–18 years and 120 controls matched for age and gender were enrolled. SIBO was assessed by glucose hydrogen breath test (GHBT) in all subjects. NAFLD was assessed in all children using abdominal imaging and laboratory findings.

Results:

Of 125 obese children enrolled, 47 (37.6%) presented intestinal dysbiosis and 78 (62.4%) were SIBO negative. Only four (3.3%) controls were SIBO positive. NAFLD was detected in 28/47 (59.5%) of the SIBO positive obese group, compared to 8/78 (10.2%) of the SIBO negative obese group (p<0.001) and 0/120 (0%) controls (p<0.001). Children from the SIBO positive obese group had higher rates of elevated aminotransferases levels: aspartate aminotransferases (ASAT) (53.1% vs. 6.4%; p<0.001) and alanine aminotransferase (ALAT) (59.5% vs. 7.6%; p<0.001), hypertension (23.4% vs. 5.1%; p=0.002) and metabolic syndrome (44.6% vs. 9%; p=0.002) compared to the SIBO negative obese group.

Conclusions:

Obese children with SIBO have an increased risk for developing NAFLD. The relationship between intestinal dysbiosis and diet can influence the gut-liver axis.

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
  2. Research funding: None declared.
  3. Employment or leadership: None declared.
  4. Honorarium: None declared.
  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Zimmet P, Alberti KG, Kaufman F, Tajima N, Silink M, et al. IDF Consensus Group. The metabolic syndrome in children and adolescents – an IDF consensus report. Pediatr Diabetes 2007;8:299–6.10.1111/j.1399-5448.2007.00271.xSearch in Google Scholar PubMed

2. Wang Y, Lobstein T. Worldwide trends in childhood overweight and obesity. Int J Pediatr Obes 2006;1:11–5.10.1080/17477160600586747Search in Google Scholar PubMed

3. Garoufi A, Grammatikos E, Kollias A, Grammatikos E, Stergiou GS, et al. Associations between obesity, adverse behavioral patterns and cardiovascular risk factors among adolescent inhabitants of a Greek island. J Pediatr Endocrinol Metab 2017;30:445–54.10.1515/jpem-2016-0134Search in Google Scholar PubMed

4. Elmaogullari S, Demirel F, Hatipoglu N. Risk factors that affect metabolic health status in obese children. J Pediatr Endocrinol Metab 2017;30:49–55.10.1515/jpem-2016-0128Search in Google Scholar PubMed

5. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, et al. Prevalence of overweight and obesity in the United States, 1999–2004. J Am Med Assoc 2006;295:1549–55.10.1001/jama.295.13.1549Search in Google Scholar PubMed

6. Loomba R, Sirlin CB, Schwimmer JB, Lavine JE. Advances in pediatric nonalcoholic fatty liver disease. Hepatology 2009;50:1282–3.10.1002/hep.23119Search in Google Scholar PubMed PubMed Central

7. Roberts EA. Pediatric nonalcoholic fatty liver disease (NAFLD): a “growing” problem? J Hepatol 2007;46:1133–42.10.1016/j.jhep.2007.03.003Search in Google Scholar PubMed

8. Stern C, Castera L. Non-invasive diagnosis of hepatic steatosis. Hepatol Int 2017;11:70–8.10.1007/s12072-016-9772-zSearch in Google Scholar PubMed

9. Rumessen JJ, Gudmand-Hoyer E, Bachmann E, Justesen T. Diagnosis of bacterial overgrowth of the small intestine.Comparison of the 14C-D-xylose breath test and jejunal cultures in 60 patients. Scand J Gastroenterol 1985;20:1267–75.10.3109/00365528509089288Search in Google Scholar PubMed

10. Donald IP, Kitchingmam G, Donald F, Kupfer RM. The diagnosis of small bowel bacterial overgrowth in elderly patients. J Am Geriatr Soc 1992;40:692–6.10.1111/j.1532-5415.1992.tb01961.xSearch in Google Scholar PubMed

11. King T. Small intestinal bacterial overgrowth and irritable bowel syndrome. J Am Med Assoc 2004;292:2213–4.Search in Google Scholar

12. Chandra S, Dutta U, Noor MT, Taneja N, Kochhar R, et al. Endoscopic jejunal biopsy culture: a simple and effective method to study jejunal microflora. Indian J Gastroenterol 2010;29:226–30.10.1007/s12664-010-0072-6Search in Google Scholar PubMed

13. Hamilton I, Worsley BW, Cobden I, Cooke EM, Shoesmith JG, et al. Simultaneous culture of saliva and jejunal aspirate in the investigation of small bowel bacterial overgrowth. Gut 1982;23:847–53.10.1136/gut.23.10.847Search in Google Scholar PubMed PubMed Central

14. Simren M, Stotzer PO. Use and abuse of hydrogen breath tests. Gut 2006;55:297–303.10.1136/gut.2005.075127Search in Google Scholar PubMed PubMed Central

15. Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol 2016;13:412–5.10.1038/nrgastro.2016.85Search in Google Scholar PubMed

16. DiBaise JK, Frank DN, Mathur R. Impact of the gut microbiota on the development of obesity: current concepts. Am J Gastroenterol 2012;1:22–7.10.1038/ajgsup.2012.5Search in Google Scholar

17. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007;56:1761–2.10.2337/db06-1491Search in Google Scholar PubMed

18. Brun P, Castagliuolo I, Di Leo V, Buda A, Pinzani M, et al. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2007;292:518–25.10.1152/ajpgi.00024.2006Search in Google Scholar PubMed

19. Centers for Disease Control Prevention, National Center for Health Statistics website. Available at: https://www.cdc.gov/growthcharts/clinical_charts.htm. Accessed on January 2, 2015.Search in Google Scholar

20. McCarthy HD, Jarrett KV, Crawley HF. The development of waist circumference percentiles in British children aged 5.0–16.9 years. Eur J Clin Nutr 2001;55:902–7.10.1038/sj.ejcn.1601240Search in Google Scholar PubMed

21. Katzmarzyk PT. Waist circumference percentiles for Canadian youth 11–18 y of age. Eur J Clin Nutr 2004;58:1011–5.10.1038/sj.ejcn.1601924Search in Google Scholar PubMed

22. Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth: a meta-analysis. Clin Gastroenterol Hepatol 2013;11:483–90.10.1016/j.cgh.2012.12.011Search in Google Scholar PubMed

23. Schwimmer JB, Dunn W, Norman GJ, Pardee PE, Middleton MS, et al. SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease. Gastroenterol 2010;138:1357–64.10.1053/j.gastro.2009.12.052Search in Google Scholar

24. Vajro P, Lenta S, Socha P, Dhawan A, McKiernan P, et al. Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN hepatology committee. J Ped Gastroenterol Nutr 2012;54:700–13.10.1097/MPG.0b013e318252a13fSearch in Google Scholar

25. Vos MB, Abrams SH, Barlow SE, Caprio S, Daniels SR, et al. NASPGHAN clinical practice guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: recommendations from the expert committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Ped Gastroenterol Nutr 2017;64:319–34.10.1097/MPG.0000000000001482Search in Google Scholar

26. Fialho A, Fialho A, Thota P, McCullough AJ, Shen B. Small intestinal bacterial overgrowth is associated with non-alcoholic fatty liver disease. J Gastrointestin Liver Dis 2016;25:159–65.10.15403/jgld.2014.1121.252.iwgSearch in Google Scholar PubMed

27. Abd El-Kader SM, El-Den Ashmawy EM. Non-alcoholic fatty liver disease: the diagnosis and management. World J Hepatol 2015;7:846–58.10.4254/wjh.v7.i6.846Search in Google Scholar PubMed

28. Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterol 1998;114:842–5.10.1016/S0016-5085(98)70599-2Search in Google Scholar

29. Sanyal AJ. Mechanisms of disease: pathogenesis of nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2005;2:46–53.10.1038/ncpgasthep0084Search in Google Scholar PubMed

30. Malhi H, Gores GJ. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis 2008;28:360–9.10.1055/s-0028-1091980Search in Google Scholar PubMed PubMed Central

31. Bruel L, Sulzenbacher G, Cervera Tison M, Pujol A, Nicoletti C, et al. α-Galactosidase/ sucrose kinase (AgaSK), a novel bifunctional enzyme from the human microbiome coupling galactosidase and kinase activities. J Biol Chem 2011;286:40814–23.10.1074/jbc.M111.286039Search in Google Scholar PubMed PubMed Central

32. Vajro P, Paolella G, Fasano A. Microbiota and gut-liver axis: their influences on obesity and obesity-related liver disease. J Pediatr Gastroenterol Nutr 2013;56:461–8.10.1097/MPG.0b013e318284abb5Search in Google Scholar PubMed PubMed Central

33. Guercio Nuzio S, Di Stasi M, Pierri L, Troisi J, Poeta M, et al. Multiple gut-liver axis abnormalities in children with obesity with and without hepatic involvement. Pediatr Obes 2016 Jun 28. doi: 10.1111/ijpo.12164.10.1111/ijpo.12164Search in Google Scholar PubMed

34. Troisi J, Pierri L, Landolfi A, Marciano F, Bisogno A, et al. Urinary metabolomics in pediatric obesity and NAFLD identifies metabolic pathways/metabolites related to dietary habits and gut-liver axis perturbations. Nutrients 2017;9:1–15.10.3390/nu9050485Search in Google Scholar PubMed PubMed Central

35. Boursier J, Mueller O, Barret M, Machado M, Fizanne L, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology 2016;63:764–75.10.1002/hep.28356Search in Google Scholar PubMed PubMed Central

36. England K, Thorne C, Pembrey L, Tovo PA, Newell ML. Age and sex-related reference ranges of alanine aminotransferase levels in children: European paediatric HCV network. J Pediatr Gastroenterol Nutr 2009;49:71–7.10.1097/MPG.0b013e31818fc63bSearch in Google Scholar PubMed

37. Nobili V, Reale A, Alisi A, Morino G, Trenta I, et al. Elevated serum ALT in children presenting to the emergency unit: relationship with NAFLD. Dig Liver Dis 2009;41:749–52.10.1016/j.dld.2009.02.048Search in Google Scholar PubMed

38. Ghoshal UC. How to interpret hydrogen breath test. J Neurogastroenterol Motil 2011;17:312–7.10.5056/jnm.2011.17.3.312Search in Google Scholar PubMed PubMed Central

39. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatol 2007;46:582–9.10.1002/hep.21768Search in Google Scholar PubMed

40. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterol 2005;7:1898–906.10.1053/j.gastro.2005.03.084Search in Google Scholar PubMed